Dabogratinib

Dabogratinib, formerly known by its development code TYRA-300, is an investigational, orally administered small-molecule tyrosine kinase inhibitor that selectively targets fibroblast growth factor receptor 3 (FGFR3).

Uses your system voice; voice and rate in settings.

Snapshot

≈ 1 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

Dabogratinib, formerly known by its development code TYRA-300, is an investigational, orally administered small-molecule tyrosine kinase inhibitor that selectively targets fibroblast growth factor receptor 3 (FGFR3). It is being developed by Tyra Biosciences for FGFR3-associated cancers and achondroplasia.

As of October 2026, its clinical development included studies in urothelial carcinoma, non-muscle-invasive bladder cancer, and children with achondroplasia. AdisInsight listed phase II development for achondroplasia, bladder cancer, and urogenital cancer, and phase I/II development for solid tumors.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1379052920 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

8 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.